Group 1 - The core viewpoint of the collaboration between Huamei Haolian and the Chinese Academy of Medical Sciences Blood Disease Hospital is to focus on mutual benefits and joint development, addressing challenges in the diagnosis and treatment of complex blood diseases through innovative cooperation in various fields such as medical services, telemedicine, and academic exchanges [1][5][7] - The Chinese Academy of Medical Sciences Blood Disease Hospital is the only tertiary specialized hospital for blood diseases in China, established in 1957, and is recognized as the largest national research-oriented medical institution for blood diseases, with over 300,000 annual patient visits and a leading expert team [3][4] - Huamei Haolian has extensive experience in medical technology services, integrating advanced digital technology platforms and global medical resources, serving over 40 million end-users through customized AI health management solutions [4][5] Group 2 - The collaboration will create a dedicated channel for Huamei Haolian's commercial insurance clients, covering the entire process from outpatient to inpatient services, significantly reducing waiting times for patients and enhancing access to quality medical resources [5][6] - A highlight of the partnership is the establishment of a remote medical consultation platform that connects domestic and international experts, allowing patients with complex conditions to receive tailored treatment plans without the need for long-distance travel [5][6] - An academic exchange platform will be developed to facilitate the transformation of academic achievements and the iteration of diagnostic technologies, supporting talent cultivation and research breakthroughs in the field of hematology [6][7] Group 3 - The strategic cooperation is based on a framework agreement aimed at meeting patient needs and establishing a foundation for long-term collaboration, with plans to continuously expand the depth and breadth of cooperation [7] - The partnership signifies an important step for Huamei Haolian in optimizing medical resource allocation and innovating service models, contributing to the construction of a blood disease diagnosis and treatment ecosystem under the "Healthy China" strategy [7]

引言：在 AI 与产业深度融合的浪潮中，合规创新成为发展的关键。浩海生命 "善食" 大模型成功备案广 东省生成式人工智能服务，既彰显其技术创新与数据安全实力，也承诺以安全透明服务，为健康管理智 能化注入新动能。 在服务公开透明性上，依据公告要求，"善食" 大模型将在服务界面显著位置或产品详情页清晰展示服 务上线编号，方便用户识别与监督，进一步增强用户信任，让服务接受公众审视。 在保障用户权益层面，合规备案是浩海生命对客户的郑重承诺。公司将严格遵循法律法规，全方位保障 用户合法权益，为用户提供安全、可靠、负责任的人工智能服务。 三、聚焦创新发展，智领行业未来方向 因数据隐私保护要求高、模型应用场景严谨，全国生成式AI备案通过率较低。"善食"大模型在技术安全 性、数据合规性、伦理风险评估等多维度严苛审核标准下突围，与中原地产、广电运通、科大讯飞等头 部企业或上市公司模型同批通过备案，且为新增 13 款备案服务里医疗健康管理领域唯一案例。截至 2025 年 3 月 31 日，全国仅有 346 款生成式人工智能服务通过国家网信办备案。"善食"大模型以其在智 能化健康管理领域的突破性应用，树立了"技术创新+伦理合规"的 ...